stockrowSarepta Therapeutics, Inc.
SRPT Healthcare Biotechnology
Sarepta Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.2 billion, up 15.6% from fiscal 2024.
- Revenue
- −4.51%
- EPS
- +46.0%
- Free cash flow
- +231.8%
- Total debt
- −17.2%
Quarter to September 2026, against a year earlier
Follow SRPT
Alert me
Sarepta Therapeutics, Inc. (SRPT) Net income
Sarepta Therapeutics, Inc.'s net income for fiscal 2025 was −$713.4M, compared with $235.2M in fiscal 2024. Over the twelve months to 30 September 2026 it was −$114.6M. Over the past ten years it has ranged from −$715.1M (fiscal 2019) to $235.2M (fiscal 2024); the current reading is higher than 18% of that period. Sarepta Therapeutics, Inc. ranks 446th of 605 Biotechnology companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | −$713.4M | — |
| FY2024 | $235.2M | — |
| FY2023 | −$536.0M | — |
| FY2022 | −$703.5M | — |
| FY2021 | −$418.8M | — |
| FY2020 | −$554.1M | — |
| FY2019 | −$715.1M | — |
| FY2018 | −$361.9M | — |
| FY2017 | −$50.7M | — |
| FY2016 | −$267.3M | — |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Sep 2026 | −$28.5M | — |
| Jun 2026 | −$4.9M | — |
| Mar 2026 | $331.0M | — |
| Dec 2025 | −$412.2M | — |
| 43 more quarters | Free account |
Against its own ten years
Net income against peers
| Company | Net income |
|---|---|
| HRMY Harmony Biosciences Holdings, Inc. compare | $178.6M |
| TRAX First Tracks Biotherapeutics, Inc. compare | $16.3M |
| TRVI Trevi Therapeutics, Inc. compare | −$51.1M |
| SRPT Sarepta Therapeutics, Inc. | −$114.6M |
| MRVI Maravai LifeSciences Holdings, Inc. compare | −$115.0M |
| MESO Mesoblast Limited compare | −$128.6M |
| MAZE Maze Therapeutics, Inc. compare | −$133.6M |
| VIR Vir Biotechnology, Inc. compare | −$184.8M |
| REPL Replimune Group, Inc. compare | −$271.0M |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item